Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1952)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 16 NOVEMBER 2026

Reference is made to the circular (the "**Circular**") of Everest Medicines Limited (the "**Company**") dated 2 November 2026 incorporating, amongst others, the notice (the "**Notice**") of the extraordinary general meeting of the Company (the "**EGM**"). Unless the context requires otherwise, the capitalized terms used herein shall have the same meanings as those defined in the Circular.

On 16 November 2026, the EGM was held by way of virtual meeting via the Online Platform and the proposed resolution as set out in the Notice was duly passed by the Shareholders by way of poll. The poll results in respect of the resolution proposed at the EGM are as follows:

Ordinary Resolution		**Number of Votes (%)**	
		For	**Against**
1.	To approve, confirm and ratify the Strategic Cooperation Framework Agreement, including the annual caps for the years ending 31 December 2026, 2027 and 2028, and the transactions contemplated thereunder.	21,113,554 (66.40%)	10,683,002 (33.60%)

Notes:

(a) As a majority of the votes were cast in favour of the resolution numbered 1, such resolution was duly passed as an ordinary resolution of the Company. The full text of the aforesaid resolution is set out in the Circular.

(b) As at the date of the EGM, (i) the total number of Shares in issue was 354,639,213 Shares; and (ii) there were no treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS). Accordingly, the total number of Shares entitling the holders to attend and vote for or against the resolution proposed at the EGM was 354,639,213 Shares.

(c) The trustees holding unvested Shares awarded under the Company's share schemes held 971,295 Shares as at the date of the EGM and were required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules.

(d) As at the date of the EGM, to the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Mr. Wei Fu and CBC Group were interested in 89,423,927 Shares. Mr. Wei Fu and CBC Group (and their associates) were required to abstain from voting on the resolution numbered 1.

(e) Save as mentioned above, no shareholder of the Company was required under the Listing Rules to abstain from voting on the resolution at the EGM and there were no Shares entitling the holder to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules.

(f) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolution at the EGM.

(g) The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

(h) The EGM was chaired by Mr. Yifang Wu, and Mr. Wei Fu, Mr. Yongqing Luo, Mr. Ian Ying Woo, Mr. Xin Sun, Ms. Yue Wang, Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang attended the EGM.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 16 November 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.